Novartis Exercises Option to Acquire Selexys Pharmaceuticals to Add Sickle Cell Disease Candidate
By Keshav Mahawar
Pharma Deals Review: Vol 2016 Issue 12 (Table of Contents)
Published: 19 Dec-2016
DOI: 10.3833/pdr.v2016.i12.2211 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Novartis has expanded its late-stage haematology pipeline with the acquisition of US-based Selexys Pharmaceuticals in a deal potentially worth US$665 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS